60 Degrees Pharmaceuticals (60 Degrees Pharmaceuticals) ROCE % : 28.08% (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is 60 Degrees Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. 60 Degrees Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2024 was 28.08%.

60 Degrees Pharmaceuticals ROCE % Historical Data

The historical data trend for 60 Degrees Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

60 Degrees Pharmaceuticals ROCE % Chart

60 Degrees Pharmaceuticals Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

ROCE %

-31.46

-112.53

60 Degrees Pharmaceuticals Quarterly Data
	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial							-	-	-	-140.54	28.08

60 Degrees Pharmaceuticals ROCE % Calculation

60 Degrees Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-1.527	/	( ( (1.297 - 23.921)	+	(7.784 - 2.835) )	/ 2 )
	=	-1.527	/	( (-22.624	+	4.949)	/ 2 )
	=	-1.527	/	-8.8375
	=	17.28 %

60 Degrees Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	1.716	/	( ( (7.784 - 2.835)	+	(8.379 - 1.104) )	/ 2 )
	=	1.716	/	( ( 4.949	+	7.275 )	/ 2 )
	=	1.716	/	6.112
	=	28.08 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

60 Degrees Pharmaceuticals (NAS:SXTP) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

60 Degrees Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of 60 Degrees Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

60 Degrees Pharmaceuticals (60 Degrees Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 60 Degrees Pharmaceuticals Inc (NAS:SXTP) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1025 Connecticut Avenue NW, Suite 1000, Washington, D.C, WA, USA, 20036

Website

https://www.60degreespharma.com

60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases through Arakoda and Celgosivir.

Executives

Charles W Allen	director	1881 N. NASH STREET, UNIT 701, ARLINGTON VA 22209
Kentucky Technology Inc.	10 percent owner	824 BULL LEA RUN, SUITE 2100, LEXINGTON KY 40511
Cheryl Xu	director	1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Paul Field	director	1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Tyrone Miller	officer: Chief Financial Officer	1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Geoffrey S Dow	director, 10 percent owner, officer: CEO and President	1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Florida State University Research Foundation Inc.	10 percent owner	200 LEVY AVENUE, BUILDING A, SUITE 351, TALLAHASSEE FL 32310
Bryan Lee Smith	officer: Chief Medical Officer	1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Stephen Toovey	director	1025 CONNECTICUT AVENUE NW, SUITE 100, WASHINGTON DC 20036